The clinical curative effect of pegylated interferon α-2a combined with ribavirin in treating chronic hepatitis C with positive autoantibodies
10.3760/cma.j.issn.1673-4904.2014.25.012
- VernacularTitle:聚乙二醇干扰素α-2a联合病毒唑治疗自身免疫抗体阳性慢性丙型肝炎的临床研究
- Author:
Xihong WANG
;
Li ZHOU
- Publication Type:Journal Article
- Keywords:
Pegylated interferon α-2a;
Ribavirin;
Chronic hepatitis C;
Autoantibodies
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(25):32-34
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the clinical curative effect of pegylated interferon α-2a (Peg-IFNα-2a) combined with ribavirin in treating chronic hepatitis C with positive autoantibodies.Methods The autoantibodies were screened in 93 cases of chronic hepatitis C patients and then the patients were divided into positive group and negative group.Both of the two groups were given therapy with Peg-IFN α-2a combined with ribavirin.The capacity of hepatitis C virus (HCV) RNA,virological response rate,and blood concentration of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were quantified before and in the process of treatment.Results Twenty-eight patients had autoantibodies,with 17 patients of antimitochondrial antibody,8 patients of anti smooth muscle antibody and 3 patients of anti-liver-kidney microsomal antibody-1.The quantity of HCV RNA and the virological response rate had no significant difference before and after treatment (P ＞ 0.05).The concentration of ALT and AST in positive group were higher than those in negative group before and in the process of treatment,while there were obvious differences only after 36 weeks of treatment (P ＜ 0.05).Conclusion Peg-IFN α-2a combined with ribavirin is effective for chronic hepatitis C for all the patients,but liver function of autoantibody negative patients have a better recovery.
